PAVmed (NASDAQ:PAVM) Price Target Lowered to $17.00 at Ascendiant Capital Markets

PAVmed (NASDAQ:PAVM) had its price target trimmed by Ascendiant Capital Markets from $20.00 to $17.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

Other research analysts have also recently issued reports about the stock. Zacks Research cut shares of PAVmed from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Weiss Ratings reissued a “sell (d)” rating on shares of PAVmed in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $17.00.

PAVmed Price Performance

NASDAQ PAVM opened at $0.36 on Wednesday. The firm has a market capitalization of $10.65 million, a P/E ratio of -0.63 and a beta of 1.09. PAVmed has a 1-year low of $0.30 and a 1-year high of $0.90. The business’s 50-day simple moving average is $0.40 and its 200-day simple moving average is $0.49.

Institutional Inflows and Outflows

An institutional investor recently raised its position in PAVmed stock. Jane Street Group LLC boosted its position in shares of PAVmed Inc. (NASDAQ:PAVM) by 392.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,676 shares of the company’s stock after purchasing an additional 41,990 shares during the period. Jane Street Group LLC owned approximately 0.31% of PAVmed worth $32,000 at the end of the most recent reporting period. Institutional investors own 19.93% of the company’s stock.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.